key: cord-0808899-l3bbl5i7
authors: Herrmann, Andreas; Maruyama, Junki; Yue, Chanyu; Lahtz, Christoph; Zhou, Heyue; Kerwin, Lisa; Guo, Whenzong; Zhang, Yanliang; Hoo, William Soo; Yei, Soonpin; Kwon, Sunkuk; Fu, Yanwen; Johnson, Sachi; Ledesma, Arthur; Zhou, Yiran; Zhuang, Yingcong; Yei, Elena; Adamus, Tomasz; Praessler, Slobodan; Ji, Henry
title: A Targeted Vaccine against COVID-19: S1-Fc Vaccine Targeting the Antigen-Presenting Cell Compartment Elicits Protection against SARS-CoV-2 Infection
date: 2020-06-30
journal: bioRxiv
DOI: 10.1101/2020.06.29.178616
sha: 3cb4717f48721a72a310431d008821b717029329
doc_id: 808899
cord_uid: l3bbl5i7

Vaccination efficacy is enhanced by targeting the antigen-presenting cell compartment. Here, we show that S1-Fc antigen delivery targeting the FcγR+ antigen-presenting cell compartment elicits anti-SARS-CoV-2 S1-antigen specific IgG production in vivo exerting biologically functional and protective activity against live virus infection, assessed in a stringent experimental virus challenge assay in vitro. The S1-domain of the SARS-CoV-2 spike protein was genetically fused to a human immunoglobulin Fc moiety, which contributes to mediate S1-Fc cellular internalization by FcγR+ antigen-presenting cells. Immediately upon administration intramuscularly, our novel vaccine candidate recombinant rS1-Fc homes to lymph nodes in vivo where FcγR+ antigen-presenting cells reside. Seroconversion is achieved as early as day 7, mounting considerably increased levels of anti-S1 IgGs in vivo. Interestingly, immunization at elevated doses with non-expiring S1-Fc encoding dsDNA favors the education of a desired antigen-specific adaptive T cell response. However, low-dose immunization, safeguarding patient safety, using recombinant rS1-Fc, elicits a considerably elevated protection amplitude against live SARS-CoV-2 infection. Our promising findings on rS1-Fc protein immunization prompted us to further develop an affordable and safe product for delivery to our communities in need for COVID-19 vaccinations.

The pandemic Coronavirus Disease 2019 , induced by Severe-Acute-Respiratory-Syndrome Coronavirus-2 (SARS-CoV-2) infection, was declared a Public Health Emergency of International Concern in January 2020 1 . In March 2020, more than 80,000 infections and 3,000 deaths were reported in China. COVID-19 became pandemic by spreading to numerous countries including the United States, Germany, Italy, Spain, Iran, Japan, Korea and more. By April 2020, the global infection rate was reported at 870,000 with 43,000 deaths 2 . In June 2020, approximately 10 million infection were estimated with 500,000 deaths caused by COVID-19 3 .

SARS-CoV-2 belongs to the virus family Coronaviridae (betacoronavirus taxon, or type II coronaviruses) 4 and is commonly known to be pathogenic to humans upon infection 5 .

Alphacoronavirus and most betacoronavirus infections manifest with symptoms similar to the common cold 6 . However, SARS-CoV-2 infection exerts an elevated pathology, manifesting as a severe atypical pneumonia, fever, acute respiratory distress syndrome (ARDS), sepsis and potentially patient death.

SARS-CoV-1 was initially identified and characterized as a novel coronavirus causing ARDS in 2003 [7] [8] [9] . Efforts have been made to develop therapeutic and prophylactic interventions. However, all efforts were retired in 2007 when the virus was eradicated from the human population by nonpharmaceutical interventions 2 . None of the vaccines had gone past clinical testing phase I 2 .

Currently, therapeutics and vaccines against SARS-CoV-2 are not available but are critically needed.

Since the initial discovery of SARS-CoV-1 in 2003, a repertoire of vaccination approaches underwent preclinical and clinical testing, ranging from attenuated virus to antigen-encoding nucleic acid sequences, differing in immunogen composition, administration format and route 2, 10 .

Pioneering antigen-specific vaccination studies identified and employed the spike protein, which was administered encoded by nucleic acid sequence, to serve as a promising immunizing antigen 11 . The spike transmembrane glycoprotein, an immunologically unique integral SARS-CoV-1 and SARS-CoV-2 protein, consists of an extracellularly exposed N-terminal S1 domain (including a receptor binding domain, RBD) engaging with host receptor ACE2 in humans 12 , followed by a S2 domain mediating virion: host-cell membrane fusion resulting in syncytia formation 12 , which is associated with aggressive disease progression 5, 9 . A transmembrane region and an intracellular carboxyterminal cytoplasmic domain complete the spike protein 12 . In 2004, Nabel and colleagues reported a promising plasmid DNA vaccine candidate against SARS-CoV-1 tested in mice, introducing the extracellular domains S1 and S2 as well as the transmembrane domain as immunizing antigen 11 . In 2020, an advanced vaccine candidate employed inactivated SARS-CoV-2 virus acquiring immunization efficacy 13 . Both studies assess promising humoral as well as adaptive immune responses, which are considered to contribute to successful vaccination and long-term protection. While the primary goal of immunization is the production of antigenspecific antibodies capable of virus neutralization and eliciting protective activity 14 , the antigenspecific education of the T cell compartment is thought to mount an antiviral response by interferon (IFN) production 15 . Furthermore, CD4 + IFN + Th1 polarization and maturation of virusantigen specific CD8 + T cells contribute to enhanced anti-viral adaptive immune responses.

Interestingly, interleukin-6 (IL-6) secretion has been found to be associated with advanced pulmonary pathology in COVID-19 patients 16 , which draws particular attention to IL-6 circuitrycounteracting IFN responses 17 and the importance of an operative adaptive immune response.

However, directing an immunization approach against COVID-19 to directly target the antigenpresenting cell (APC) compartment, which has been emphasized by Steinman and colleagues to dramatically enhance both, the humoral and adaptive immune response 18 , remains elusive.

Here, we report a unique targeted immunization approach against COVID-19, directly delivering the immunizing S1-Fc antigen to FcR + APCs. Our immunization approach focusses on the SARS-CoV-2 spike protein S1 domain serving as the viral antigen. We genetically fused the S1 domain to the Fc moiety of human immunoglobulin IgG1, which facilitates cellular internalization of S1-Fc by FcR + APCs, such as dendritic cells and macrophages as well as B cells, where IgG1-Fc is known to crossreact with murine FcR 19 . Targeted immunization with rS1-Fc protein potentially affords low dose and therefore safe immunization, associated with enhanced desired immune responses 18 . Immediately after rS1-Fc administration, rS1-Fc homes to the inguinal lymph node where FcR + APCs reside. Furthermore, rS1-Fc immunization induces rapid seroconversion and mounts a considerably elevated production of S1-specific antibodies in vivo, indicating a robust S1-Fc-induced humoral immune response. Interestingly, persistent delivery of S1-Fc by immunization with non-expiring S1-Fc dsDNA induces a potent adaptive immune response, including immunization-dose-dependent Th1 polarization and CD8 + IFN + effector T cell maturation in vivo. Moreover, high-dose administration of non-expiring S1-Fc dsDNA induces the education of anti-S1 antigen-specific CD8 + T cells. However, in direct comparison, immunization with low-dose recombinant rS1-Fc protein induces the production of S1-specific antibodies, exerting considerably elevated neutralization activity against SARS-CoV-2 virus in vitro. Hence, our promising findings prompted us to initiate further proof-of-concept/efficacy studies as well as toxicologic studies, employing rS1-Fc immunization followed by live SARS-Cov-2 virus challenge, to further develop an affordable, readily scalable manufacturing and safe product for delivery to our communities in need for COVID-19 vaccinations.

The S1-Fc fusion protein serves as the antigen to achieve immunization. The human immunoglobulin Fc moiety is thought to engage with FcR + expressing cells such as dendritic cells, macrophages and B cells, thus, targeting the antigen-presenting cell compartment 20 . The S1 domain of the SARS-CoV-2 spike protein serves as the immunogenic antigen to mount antiviral humoral and adaptive immune responses. Upon production of a linear S1-Fc encoding dsDNA, harboring a constitutively active promoter and a cell secretion sequence (Fig. 1A) , we assessed S1-Fc protein secretion by murine muscle cells upon delivery. Linear S1-Fc encoding dsDNA was internalized immediately upon electroporation by murine fibroblasts and muscle cells with considerably high efficacy as shown by flow cytometry (Fig. 1B) , which could be validated by confocal microscopy (Fig. 1C ). Subsequently, critical secretion of S1-Fc protein, which is thought to serve as the immunizing antigen, was detected in muscle cell culture supernatant (Fig. 1D) .

Notably, S1-Fc protein was detected in the biceps femoris muscle 44 days after administration, which is indicative of continuous non-exhausting S1-Fc protein de novo synthesis and S1-Fcprotein release (Supplemental Fig. 1A) . Moreover, S1-Fc protein was found internalized by dendritic cell species in biceps femoris, suggesting operative targeting of the FcR + APC compartment (Supplemental Fig. 1B ).

Recombinant rS1-Fc protein chimera was produced in CHO cells and subjected to analytical sizeexclusion chromatography showing a distinct elution of rS1-Fc monomer (84.5%). However, a minor molecular population (13.2%) eluted as self-assembled (rS1-Fc)n aggregate (Supplemental Fig. 2A ) which might by owed to intrinsic oligomerization activity of the SARS-CoV-2 spike protein 21 . Notably, gel electrophoretic analysis showed reduced rS1-Fc aggregation activity in repeated protein production (Supplemental Fig. 2B ). rS1-Fc immunologic identity was validated by immunodetection of S1 and Fc upon Western blotting procedure ( Fig. 2A) . Chimeric rS1-Fc is readily internalized by murine RAW264.7 macrophages in vitro (Fig. 2B ) and can be found throughout the cell cytoplasm as well as the cell nucleus as demonstrated by confocal laserscanning microscopy (Fig. 2C) . Importantly, rS1-Fc engages with ACE2 as assessed by ELISA (Fig. 2D) . The S1 domain of the SARS-CoV-2 spike protein binding to host receptor ACE2 was emphasized to contribute critically to the initiation of host cell infection 12 . However, rS1-Fc binding to ACE2 indicates operative functionality, and furthermore, binding represents a decoy activity by latent competition with viral spike protein for ACE2 binding, potentially reducing host cell virus susceptibility. Moreover, targeted delivery of rS1-Fc to the APC compartment is thought to be mediated by Fc:FcR interaction, which requires rS1-Fc homing to secondary lymphoid organs once administered. Intramuscular administration into the biceps femoris facilitates rS1-Fc migration to the inguinal lymph node within 1 hour as demonstrated by longitudinal nIR fluorescence imaging (Fig. 2E , F). Homing to the lymph node critically enhances the exposure of rS1-Fc to FcR expressing APCs and favors its cellular internalization and intended processing.

Interestingly, S1-protein + splenic APCs were observed 44 days after initial intramuscular administration of rS1-Fc (Fig. 2G ).

Freshly isolated splenic APCs, such as CD11c + dendritic cells, F4/80 + macrophages and CD19 + B cells, readily internalize rS1-Fc within 30 min as assessed by flow cytometric analysis (Fig. 3A) .

Notably, prolonged exposure of splenic APCs to rS1-Fc did not result in increased cellular load, which is suggesting a cytologic limitation in antigen uptake. However, blocking CD16/32 + FcR resulted in considerably reduced rS1-Fc cellular internalization, indicating functional targeting of rS1-Fc into the FcR + APC compartment (Fig. 3B ).

Immunization of mice with either linearized dsDNA encoding S1-Fc or recombinant rS1-Fc protein was administered into the biceps femoris intramuscularly. Repeated "boosting" immunization was scheduled at day 21 after initial immunization administration. Blood serum of immunized mice was collected weekly to facilitate monitoring of anticipated immune responses (Fig. 4A ).

Immunization of mice with linearized dsDNA encoding S1-Fc mounted a significant and robust CD4 + IFN + Th1 polarization in vivo in a dose-dependent manner (Fig. 4B) . Moreover, S1-antigen specific CD8 + T cells isolated from spleen accumulated upon immunization at increased dose ( Fig. 4C ). Furthermore, high dose immunization favored CD8 + IFN + effector T cell in vivo education in a dose-dependent manner (Fig. 4D ). Thus, dose-dependent adaptive immune responses upon administration of non-expiring S1-Fc dsDNA indicate, that considerably elevated dosing with non-expiring S1-Fc dsDNA is required to elicit a desired adaptive T cell immune response, continuously feeding S1-antigen systemically. In turn, the humoral B cell immune response is sensitive to reduced immunization doses. Complete seroconversion is detectable at day 10 upon initial immunization with both, 50 g and 20 g of administered non-expiring S1-Fc dsDNA, mounting similar levels of S1-specific serum IgG antibodies. However, administration of 2 g non-expiring S1-Fc dsDNA did not suffice to induce a robust production of S1-specific serum IgG antibodies (Fig. 4E) . Remarkably, immunization with recombinant rS1-Fc facilitated accelerated seroconversion detectable at day 7, mounting considerably increased levels of S1specific serum IgG antibodies. Production of S1-specific serum IgG antibodies in vivo experiences a decrease at day 24, which might be owed to the anticipated feedback inhibition loop mediated by FCR-B activity, facilitating self-regulatory termination of antibody production [22] [23] [24] [25] . However, upon administration of a repeated "boosting" immunization at day 21, S1-specific serum IgG antibody production recovered by day 28 resulting in considerably elevated and higher anti-S1

IgG serum levels (Fig. 4F) . Moreover, murine blood serum seropositive for anti-S1 IgG significantly reduced the interaction of the viral S1-domain and host receptor ACE2 at high dilution, indicating production of a highly potent anti-S1 IgG serum antibody population induced by rS1-Fc protein immunization (Fig. 4G) . Importantly, collected blood serum seropositive for anti-S1 IgG elicits protection against live SARS-CoV-2 infection in a stringent experimental virus challenge assay. However, although continuous S1-Fc expression and antigen production is facilitated by immunization with non-expiring S1-Fc-encoding dsDNA, we observed that high dose immunization with non-expiring S1-Fc-encoding dsDNA elicits protection up to 50% only. In contrast, low-dose immunization with recombinant rS1-Fc administered intramuscularly mounted considerable increased protection activity (80%) (Fig. 4H) . Interestingly, routing rS1-Fc administration via intravenous injection resulted in a similar protection efficacy (77.7%), indicating that rS1-Fc immunization propagates a robust humoral immune response. Hence, immunization against SARS-CoV-2 employing rS1-Fc protein unfolds rapid seroconversion and production of anti-S1-specific IgG eliciting protection capacity.

Our results show that targeted immunization with S1-Fc immediately directed to the FcR + APC compartment induces a robust humoral immune response in preclinical testing eliciting protective activity against SARS-CoV-2 infection. S1-Fc immunization triggers rapid seroconversion, resulting in considerably elevated production of S1-specific antibodies in vivo. Furthermore, immunization with recombinant rS1-Fc protein improves the inhibitory activity of anti-S1 IgG antibodies, protecting from live SARS-Cov.2 infection in vitro. Interestingly, the education of an S1-antigen specific adaptive immune response is highly dose-sensitive. At high-dose immunization using non-expiring S1-Fc-encoding dsDNA, we demonstrate the desired Th1 polarization and effector CD8 + IFN + T cell maturation. Moreover, high-dose immunization with non-expiring S1-Fc-encoding dsDNA mounts S1-antigen specific CD8 + T cell education, which remained undetectable using low-dose immunization with rS1-Fc. Immunization dose-sensitivity shaping the adaptive immune response sheds light on potentially required elevated doses and/or an increased dose frequency for improved adaptive immune responses.

Impressive results were reported in a recent preclinical study, employing the full-length S glycoprotein of SARS-CoV-2 as immunogen, encoded and administered as plasmid DNA 26 However, immunization introducing double-stranded, single-stranded DNA or RNA species including plasmids, inevitably raises the concern of an undesired Toll-like receptor (TLR) response, mediating uncontrolled cytokine secretion and potentially resulting in diseasepromoting cytokine-release syndrome (CRS) and life-threatening inflammatory responses 27, 28 .

TLRs are known to detect microbial infection extra-and intracellularly 29 , inducing the activation of an inflammatory response, including but not restricted to IL-6 production 30 Moreover, although adenovirus-mediated introduction of immunogen, encoded by dsDNA inside the viral capsoid, aggressively achieves elevated antigen presentation over a considerably extended period of time, the systemic presence of adenovirus per se elicits unfavorable consequences 32, 33 . An undirected/anergic adaptive immune response, the education of inflammatory IL-10 producing CD4 + T regulatory cells reducing desired anti-viral CD8 + T cell efficacy, and raising undesired adverse reactions were reported 32, 33 , abandoning patient safety and is associated with unpredictable prognosis. Hence, the undirected and uncontrolled introduction of a transgene in humans for the purpose of immunization therapy must be considered scientifically premature, requires in depth clinical testing to determine safety exit strategies, and is not fit for delivery to the public at large scales, which are required to control the COVID-19 pandemic.

Our ongoing comprehensive studies as well as others 26, 32, 33 indicate, that considerable amounts of immunogen are required to achieve education of an IFN + adaptive immune response. However, low-dose immunization with rS1-Fc targeting the FcR + APC compartment represents an operative immunization strategy achieving rapid seroconversion and mounting considerably high levels of anti-S1 specific antibodies eliciting protective activity. Further preclinical studies tailored to improve the antigen-specific adaptive immune response in the circuitry of immunization by targeted rS1-Fc protein are required, guiding us to a mild, safe and protecting targeted rS1-Fc vaccination against COVID-19.

Mice and cell culture. -For intramuscular antigen challenge, C57BL/6 female mice 5-6 weeks old were injected with either 100 g rS1-Fc, or electroporation was applied delivering 2 g, 20 g, or 50 g linear dsDNA encoding S1-Fc. For intramuscular antigen challenge, C57BL/6 female mice were injected with 100 g rS1-Fc intravenously. Antigen challenge at day 1 and day 22 was administered into the biceps femoris muscles of mice. Peripheral blood was collected from anaesthetized mice once/week via retro-orbital route. Murine NIH/3T3 fibroblasts, C2C12 myoblasts and 264.7 RAW macrophages were obtained from ATCC and subcultured according to the vendor's instructions. Single-cell suspensions from spleens were freshly isolated immediately after dissection. Briefly, spleens were disrupted using cell strainer, followed by red cell depletion.

Production of linearized S1-Fc-encoding S1-Fc dsDNA fragment. -The plasmid pAAV S1-Fc was digested with New England Biolabs (NEB) Restriction Enzymes Pvu I-HF (Cat. No. R3150), Sph I-HF (Cat. No. R3182) and Mlu I-HF (Cat. No. R3198) at 37°C for 2.5 hours. The resulted fragments were separated by 1% agarose DNA gel electrophoresis. The desired S1-Fc fragment was cut from the gel and extracted to recover S1-Fc DNA with NucleoSpin Gel and PCR Cleanup kit from Macherey Nagel (Cat. No. 740609). The S1-Fc dsDNA was amplified by 2-step nested PCR. The gel recovered S1-Fc DNA was used as the template for the 1st PCR of the nested PCR. Both 1st PCR and 2nd PCR were performed by using PrimeSTAR HS DNA polymerase immunostaining procedure as previously described 34 . Briefly, tissues were fixed with 2% paraformaldehyde and permeabilized with icecold methanol for 30 min gently shaking. Wax circles were applied and Image IT signal enhancer (Invitrogen) was used for signal quenching.

Upon blocking tissue with PBS containing 10 % mouse serum and 2.5% goat serum for 1 h at RT, primary antibodies against S1 or dendritic cell marker (clone 33D1) were incubated diluted in blocking buffer in a wet chamber over night at 4°C. Upon rinsing, fluorescent secondary antibodies diluted in blocking buffer were incubated together with DNA staining DRAQ7 (abcam) for 4 hours protected from light and sections were mounted in Mowiol (Sigma-Aldrich). Stained sections were analyzed by confocal laser-scanning microscopy using a cLSM510Meta Microscope (Zeiss). 

We thank our staff at Sorrento Therapeutics Inc. to tirelessly support our efforts.

HJ drafted the study design, orchestrated the study, and edited the manuscript, AH aligned Linear dsDNA encoding S1-Fc was generated by PCR-based amplification and subjected to analytical DNA gel electrophoresis, assessing accurate size and excluding undesired intermediate product. (B) Cellular internalization of fluorescently labeled dsDNA encoding S1-Fc was assessed by flow cytometry immediately after electroporation procedure, gating on dsDNA encoding S1-Fc + cells (red). (C) Cellular internalization of S1-Fc-dsDNA was validated by confocal microscopy. Scale, 50 mm. (D) Produced S1-Fc protein secreted by C2C12 muscle cells within 96 h after electroporation was assessed from collected cell supernatant and analyzed by MSD assay. SD shown. T-test: **) P < 0.01. Generated rS1-Fc is functionally binding to human ACE2 as shown by ELISA. (E, F) rS1-Fc homes to the inguinal lymph node within an hour upon administration into the biceps femoris as determined by longitudinal nIR imaging of the lymphatics. SD shown. (G) rS1-Fc and/or S1 and/or processed S1 peptide was found 44 d upon initial administration in splenic APCs as assessed by flow cytometry. 4: rS1-Fc immunization elicits early seroconversion, facilitating anti-S1specific IgG production protecting against live SARS-CoV-2 challenge. (A) Schematic representation of mice immunization and blood serum collection schedule as indicated. (B) Dose-dependent and significant Th1 polarization upon high-dose non-expiring immunization with S1-Fc dsDNA as analyzed by fold-increased education of CD4 + IFNg + versus CD4 + IL-4 + T cells in vivo assessed by flow cytometry (right panel). Gating exemplary shown (left panels). (C) S1-antigen-specific CD8 + T cell accumulation assessed by MHC-tetramer/S1peptide flowcytometric analysis of cognate TCR expressed by CD8 + T cells. (D) Immunization-dose-dependent maturation of effector CD8 + IFNg + T cells was assessed by flow cytometry and quantified. (E) Rapid seroconversion and production of S1-specific IgG antibody upon immunization with S1-Fc dsDNA doses as indicated, or (F) rS1-Fc protein, assessed by ELISA. (G) Anti-S1 IgG seropositive blood serum significantly reduces viral S1:ACE2 host receptor interaction as shown by ELISA at high serum dilutions (1:16), and (H) elicits protective activity against live SARS-CoV-2 virus challenge, as assessed in a stringent experimental virus challenging assay employing VeroE6 cells. All n=10. SD shown; T-test: *) P<0.05.

Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern

Emerging coronaviruses: Genome structure, replication, and pathogenesis

COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

A novel coronavirus associated with severe acute respiratory syndrome

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

New Vaccine Technologies to Combat Outbreak Situations

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Rapid development of an inactivated vaccine candidate for SARS-CoV-2

Vaccines for the twenty-first century society

COVID-19: immunopathology and its implications for therapy

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Mutational switch of an IL-6 response to an interferon-gamma-like response

The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells

Affinity of human IgG subclasses to mouse Fc gamma receptors

Fc gamma receptors: glycobiology and therapeutic prospects

Oligomerization of the SARS-CoV S glycoprotein: dimerization of the N-terminus and trimerization of the ectodomain

FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications

Inhibitory Fc gamma receptors: from gene to disease

The Human FcgammaRII (CD32) Family of Leukocyte FcR in Health and Disease

Fcgamma receptors: old friends and new family members

Immunogenicity of a DNA vaccine candidate for COVID-19

The history of Toll-like receptors -redefining innate immunity

Toll-like receptors and innate immunity

Microbial sensing by Toll-like receptors and intracellular nucleic acid sensors

Toll-like receptor signaling pathways

Modulation of adaptive immunity with Toll-like receptors

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells

STAT3 Activation-Induced Fatty Acid Oxidation in CD8(+) T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth

Correspondence and other requests should be addressed to Andreas Herrmann, aherrmann@sorrentotherapeutics.com, Slobodan Paessler, slpaessl@utmb.edu, and Henry Ji,hji@sorrentotherapeutics.com.